Agovirax
  • Home
  • Product info
  • Viral respiratory infections
  • Viruses
  • Publications
  • Shop
  • Contacts
  • Menu

Iota-carrageenan

(active substance of AGOVIRAX) inhibits the cell entry of SARS-CoV-2

Iota - carrageenan

(active substance of AGOVIRAX) stops viral replication by inhibiting the attachment of viruses to cells

Iota-carrageenan

(active substance of AGOVIRAX) is a broad-spectrum clinically proven therapy against viral infections of the respiratory tract

Even if AGOVIRAX

cannot prevent completely an infection by SARS-CoV-2, it may strongly reduce the risk of an infection and virus spread

Indicated for prophylaxis and treatment of respiratory infections caused by viruses in adults and children from 1 year of age.

Agovirax Product info

Therapeutic indications of Agovirax
Agovirax safety profile
Agovirax use and method of administration
Mode of action of Agovirax
Agovirax unique filter system
Agovirax composition

Viral respiratory infections

Definition
Common cold
Epidemiology
Signs and symptoms
Prophylaxis and cold management
Prognosis, complications

Viruses

What is a virus?
Rhinovirus Infections
Adenovirus infections
Coronavirus
Respiratory syncytial virus (RSV)
Influenza virus
Routes of transmission
Seasonal variations
Common cold prevention tips
Interesting facts about the common cold

Contacts

GryNumber Health company info
Contact Us

© Copyright - Agovirax

Iota-carrageenan (active substance of Agovirax) inhibits the cell entry of SARS-CoV-2

The latest in vitro study confirmed, that “iota-carageenan inhibits the cell entry of SARS-CoV-2 (…), which suggests that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment also for SARS-CoV-2 infections“. ¹

 1. Morokutti-Kurz, Graf, Grassauer et al. SARS-CoV-2 in-vitro neutralization assay reveals inhibition of virus entry by iota-carrageenan. Pre-Peer review, July 2020.

Scroll to top